Mannkind (MNKD) Construction in Progress (2021 - 2022)
Mannkind (MNKD) reported Construction in Progress of $7.7 million for Q1 2022, up 63.83% on a QoQ basis from $4.7 million in Q4 2021.
Mannkind (MNKD) has 2 years of Construction in Progress data on file, last reported at $7.7 million in Q1 2022.
- Quarterly Construction in Progress changed N/A year-over-year to $7.7 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $7.7 million (changed N/A YoY) and the FY2021 annual result came in at $4.7 million, changed N/A from the prior year.
- Construction in Progress grew to $7.7 million in Q1 2022 per MNKD's latest filing, from $4.7 million in the prior quarter.
- Across five years, Construction in Progress topped out at $7.7 million in Q1 2022 and bottomed at $1.6 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 7.70 Mn |
| Dec 31, 2021 | 4.70 Mn |
| Sep 30, 2021 | 1.60 Mn |